Health Canada Enables Phase 3 Study of Avigan Tablets For Treating COVID-19 Patients

Appili Therapeutics Inc. announced the initiation of its Phase 3 Post-Exposure Prophylaxis for COVID-19 (PEPCO) study to evaluate Avigan tablets (favipiravir) in the prevention of COVID-19. And, Health Canada has provided a ‘No Objection Letter’ for Appili’s proposed study.

In September 2020, the U.S. FDA previously accepted a submission of a protocol amendment to conduct the trial in the USA.

This is the second Phase 3 study Appili has announced to evaluate the utility of Avigan tablets against COVID-19 in the community setting. The other study also known as the PRESECO study is evaluating Avigan for the treatment of adults with mild-to-moderate symptoms of COVID-19.